Related Experiment Video

Updated: Jun 8, 2025

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
05:34

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

498

Targeted therapeutic strategies for the kidney

Fei Yuan1,2, Lilach O Lerman1,3

  • 1Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA.

Expert Opinion on Therapeutic Targets
|November 4, 2024
PubMed
Abstract

Insights

Novel kidney-targeted therapies show promise for treating renal disorders, offering new hope. However, challenges in clinical translation require further research and development for effective renal disorder treatments.

Area of Science:

  • Nephrology
  • Biomedical Engineering
  • Pharmacology

Background:

  • Kidney diseases present a significant global health challenge with limited effective treatments.
  • Developing novel therapeutic strategies is crucial to delay or reverse kidney disease progression.
  • Targeted therapies offer a promising approach to improve treatment outcomes for renal disorders.

Purpose of the Study:

  • To review recent advancements in kidney-targeted therapies.
  • To explore various modalities including gene, peptide, protein, cell-based, and nanoparticle delivery systems.
  • To discuss the clinical applications, future prospects, and challenges of these targeted therapies for renal disorders.

Main Methods:

  • Comprehensive literature review of targeted therapies for kidney diseases.
  • Analysis of different delivery systems and therapeutic agents.
  • Evaluation of current clinical applications and future potential.

Main Results:

  • Advances in targeted therapies have shown potential to enhance treatment outcomes for renal conditions.
  • Various approaches like gene therapy, peptides, proteins, cell-based therapies, and nanoparticles are being investigated.
  • Localized delivery routes are also being explored for improved efficacy.

Conclusions:

  • Targeted therapies hold significant promise for improving the management of kidney diseases.
  • Clinical translation is hindered by the complex renal structure and a lack of specific biomarkers.
  • Overcoming challenges in preclinical research and clinical application is essential for realizing the full potential of kidney-targeted therapies.
Keywords:
Kidney-targeted therapiescell-based therapygene-targeted therapylocalized delivery routesnanoparticlespeptides and proteins targeted therapy

More Related Videos

Direct Drug Delivery to Kidney via the Renal Artery11:18

Direct Drug Delivery to Kidney via the Renal Artery

Published on: April 17, 2021

7.2K
Delivery of Exogenous Artificially Synthesized miRNA Mimic to the Kidney Using Polyethylenimine Nanoparticles in Several Kidney Disease Mouse Models07:01

Delivery of Exogenous Artificially Synthesized miRNA Mimic to the Kidney Using Polyethylenimine Nanoparticles in Several Kidney Disease Mouse Models

Published on: May 10, 2022

1.5K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
391
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
498
Drug Elimination by Renal Route: Tubular Secretion01:15

Drug Elimination by Renal Route: Tubular Secretion

Once the process of glomerular filtration is completed, blood carrying unfiltered drug molecules traverses through efferent arterioles and makes its way into the peritubular capillaries in the proximal tubule. A variety of carriers play a pivotal role in actively secreting drugs from these peritubular capillaries into the tubular fluid. The organic anion transporter transfers acidic drugs, against an electrochemical gradient, from the peritubular capillaries into the renal tubule cells and...
2.2K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.0K
Renal Drug Excretion: Tubular Secretion01:28

Renal Drug Excretion: Tubular Secretion

Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...
144